Trial Profile
A Randomized, 26-week, Open-label, 2-treatment Arm, Parallel Group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed-ratio Combination (Soliqua) Titrated Using a Simple Titration Algorithm (One Unit Daily Adjustment) Compared With Insulin Glargine/Lixisenatide Fixed-ratio Combination (Soliqua) Titrated by Weekly Adjustment in Patients With Type 2 Diabetes Mellitus (T2DM)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms LixilanOne CAN
- Sponsors Sanofi
- 01 Oct 2022 Results of a sub-study assessing ease of transitioning from basal insulin to fixed-ratio combination published in the Diabetes, Obesity and Metabolism
- 29 Jun 2021 Primary endpoint (Change in glycated hemoglobin (HbA1c)%) has been met, according to Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
- 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association